Misplaced Pages

FBX-101

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Experimental gene therapy
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2023)

FBX-101 is an experimental gene therapy delivered via adeno-associated virus rh10 vector to the GALC gene. It is developed by Forge Biologics to treat Krabbe disease.

References

  1. Hordeaux, Juliette; Jeffrey, Brianne A.; Jian, Jinlong; Choudhury, Gourav R.; Michalson, Kristofer; Mitchell, Thomas W.; Buza, Elizabeth L.; Chichester, Jessica; Dyer, Cecilia; Bagel, Jessica; Vite, Charles H.; Bradbury, Allison M.; Wilson, James M. (1 May 2022). "Efficacy and Safety of a Krabbe Disease Gene Therapy". Human Gene Therapy. 33 (9–10): 499–517. doi:10.1089/hum.2021.245. PMC 9142772. PMID 35333110.
  2. Bradbury, Allison M.; Bagel, Jessica H.; Nguyen, Duc; Lykken, Erik A.; Pesayco Salvador, Jill; Jiang, Xuntian; Swain, Gary P.; Assenmacher, Charles A.; Hendricks, Ian J.; Miyadera, Keiko; Hess, Rebecka S.; Ostrager, Arielle; ODonnell, Patricia; Sands, Mark S.; Ory, Daniel S.; Shelton, G. Diane; Bongarzone, Ernesto R.; Gray, Steven J.; Vite, Charles H. (10 August 2020). "Krabbe disease successfully treated via monotherapy of intrathecal gene therapy". Journal of Clinical Investigation. 130 (9): 4906–4920. doi:10.1172/JCI133953. PMC 7456224. PMID 32773406.
  3. Escolar, Maria; Lugt, Mark Vander; Poe, Michele; Greco, Melissa; Werling, Keith; De Silva, Erandi; Ruiz, Juan; Szabolcs, Paul (2023). "P014: First-in-human phase 1/2 trial of intravenous FBX-101 with cord blood transplantation increases GALC, brain and motor development in infantile Krabbe". Genetics in Medicine Open. 1 (1): 100024. doi:10.1016/j.gimo.2023.100024.
  4. Labant, MaryAnn (1 December 2022). "Cell and Gene Therapy Industry Feels Growing Pains: Signs of greater maturity in the industry include scalable platforms, improved plasmids and vectors, streamlined processes, and regulatory discussions". Genetic Engineering & Biotechnology News. 42 (12): 38, 40–42. doi:10.1089/gen.42.12.14. S2CID 254532949.
Category: